Lecanemab

Lecanemab (development code BAN2401) is an experimental drug jointly developed by Biogen and Eisai that is currently in clinical trials for the treatment of Alzheimer's disease.[1][2] It is a monoclonal antibody consisting of the humanized version[3] of a mouse antibody mAb158 that recognizes protofibrils and prevents amyloid beta deposition in animal models of Alzheimer's disease.[4]

Lecanemab
Monoclonal antibody
TypeWhole antibody
SourceHumanized
TargetBeta amyloid
Clinical data
Other namesBAN2401
ATC code
  • none
Legal status
Legal status
  • Investigational
Identifiers
CAS Number
DrugBank
ChemSpider
  • none
UNII
KEGG

In July 2022, the U.S. Food and Drug Administration (FDA) accepted an application for accelerated approval for lecanemab and granted it Priority Review status.[5]

In September 2022 Biogen announced[5][6] positive results from an ongoing Phase 3 clinical trial.[7]

See also

Aducanumab, another monoclonal antibody medication for Alzheimer's disease

References
  1. Clinical trial number NCT01767311 for "Study to Evaluate Safety, Tolerability, and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease" at ClinicalTrials.gov
  2. Devlin H (September 28, 2022). "Success of experimental Alzheimer's drug hailed as 'historic moment'". The Guardian. Archived from the original on September 28, 2022.
  3. Lannfelt L, Möller C, Basun H, Osswald G, Sehlin D, Satlin A, Logovinsky V, Gellerfors P (2014). "Perspectives on future Alzheimer therapies: amyloid-β protofibrils - a new target for immunotherapy with BAN2401 in Alzheimer's disease". Alzheimer's Research & Therapy. 6 (2): 16. doi:10.1186/alzrt246. PMC 4054967. PMID 25031633.
  4. Söllvander S, Nikitidou E, Gallasch L, Zyśk M, Söderberg L, Sehlin D, Lannfelt L, Erlandsson A (March 2018). "The Aβ protofibril selective antibody mAb158 prevents accumulation of Aβ in astrocytes and rescues neurons from Aβ-induced cell death". Journal of Neuroinflammation. 15 (1): 98. doi:10.1186/s12974-018-1134-4. PMC 5875007. PMID 29592816.
  5. "Lecanemab Confirmatory Phase 3 Clarity Ad Study Met Primary Endpoint, Showing Highly Statistically Significant Reduction of Clinical Decline in Large Global Clinical Study of 1,795 Participants With Early Alzheimer's Disease". Biogen. September 27, 2022. Retrieved September 28, 2022.
  6. Robbins R, Belluck P (September 27, 2022). "Alzheimer's Drug Slows Cognitive Decline in Key Study". New York Times. Retrieved September 28, 2022.
  7. "A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease (Clarity AD)". ClinicalTrials.gov. 11 July 2022. Retrieved September 28, 2022.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.